NCT04700943

Brief Summary

Awake thoracic surgery is a feasible and safe alternative to general anesthesia for pulmonary biopsy in interstitial lung disease patients, but there is still no evidence as to its superiority in terms of outcome. However, there is extensive literature about the effect of anesthetic drugs and surgery on diaphragmatic function. Furthermore, in thoracic surgery, diaphragmatic dysfunction was associated with a higher occurrence of postoperative pulmonary complications. To assess the impact of general anesthesia on diaphragmatic function, the investigators conducted an observational prospective trial. The investigators measured both diaphragmatic excursion and Thickening Fraction at baseline and 12 hours after surgery together with pulmonary function tests and gas exchange data.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
41

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Feb 2019

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

February 1, 2019

Completed
1.7 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 30, 2020

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2021

Completed
3 days until next milestone

First Submitted

Initial submission to the registry

January 4, 2021

Completed
4 days until next milestone

First Posted

Study publicly available on registry

January 8, 2021

Completed
Last Updated

January 11, 2021

Status Verified

January 1, 2021

Enrollment Period

1.7 years

First QC Date

January 4, 2021

Last Update Submit

January 7, 2021

Conditions

Keywords

Ultrasoundsdiaphragmatic functionthoracic surgeryregional anesthesia

Outcome Measures

Primary Outcomes (1)

  • Diaphragmatic maximal function

    Measured with diaphragmatic excursion

    12 hours

Secondary Outcomes (2)

  • Pain scores

    24 hours

  • Postoperative Nausea and Vomiting

    24 hours

Study Arms (2)

Regional awake anesthesia

In non-intubated patients, an epidural catheter was placed at T5-T6. An anesthetic load of 0,5 mg/kg of ropivacaine was administered to reach anesthesia of the thoracic wall. Adjunctive local anesthetic infiltration of the incision site was performed by the surgeon with 2% lidocaine and 7,5% Ropivacaine. The cumulative dose of anesthetics drugs was computed as not to exceed the recommended dosage. To improve patient comfort through the procedure, sedation with Target Controlled Infusion of propofol (using Schnider algorithm) and low dose remifentanil (0,05 mcg/kg/min) was also administered.

Procedure: Regional awake anesthesia

General anesthesia

Either epidural block or an interfascial plane block of the thoracic wall, such as serratus anterior plane block or erector spinae plane block, were performed. Patients were then anesthetized with Propofol plus opiates (usually remifentanil) and muscle paralysis was achieved with Rocuronium.

Interventions

We want to assess the impact of regional anesthesia on diaphragmatic function in patients undergoing Video-assisted thoracoscopic surgery pulmonary biopsy in interstitial lung disease

Regional awake anesthesia

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients scheduled for lung biopsy were enrolled prospectively starting from February 2019 to September 2020.

You may qualify if:

  • Patients scheduled for lung biopsy from February 2019 to September 2020

You may not qualify if:

  • pregnancy,
  • Body Mass Index \>35,
  • Inability to provide informed consent,
  • American Society of Anesthesiologists physical status classification score of IV
  • Recommended postoperative ICU care

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

AOU Città della Salute e della Scienza di Torino

Turin, 10100, Italy

Location

Study Officials

  • Luca Brazzi, Professor

    University of Torino

    STUDY CHAIR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

January 4, 2021

First Posted

January 8, 2021

Study Start

February 1, 2019

Primary Completion

September 30, 2020

Study Completion

January 1, 2021

Last Updated

January 11, 2021

Record last verified: 2021-01

Locations